All In Biotech

Drugs by condition

Drugs approved for eosinophilic esophagitis

Brand-name prescription drugs and biologics whose FDA label lists eosinophilic esophagitis as an approved use. Matched on the label phrases: "eosinophilic esophagitis".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

2

Still marketed, NDA or BLA

Drug classes

2

Novel drugs

1

New molecular entities and new biologics

In development

6

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for eosinophilic esophagitis.

  • Eohilia (Budesonide) · Takeda Pharms USA Breakthrough therapyPriority reviewOrphanFeb 9, 2024
  • Dupixent (Dupilumab) · Regeneron Pharmaceuticals NovelBreakthrough therapyPriority reviewOrphanMar 28, 2017

All approved drugs for eosinophilic esophagitis, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Interleukin-4 Receptor alpha Antagonist (1)

  • Dupixent Dupilumab · Regeneron Pharmaceuticals · 2017

Corticosteroid (1)

  • Eohilia Budesonide · Takeda Pharms USA · 2024

Drugs in development for eosinophilic esophagitis

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • barzolvolimabCDX-0159Phase 37 trials

    Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria

  • cendakimabCC-93538, BMS-986355Phase 31 trial

    Bristol Myers Squibb · Eosinophilic Esophagitis

  • SolrikitugPhase 22 trials

    Uniquity One (UNI) · Eosinophilic Esophagitis (EoE), COPD

  • EP-104GIPhase 21 trial

    Eupraxia Pharmaceuticals Inc. · Eosinophilic Esophagitis

  • NDX-3315Phase 21 trial

    NexEos Diagnostics, Inc. · Eosinophilic Esophagitis

  • NDX-3324Phase 21 trial

    NexEos Diagnostics, Inc. · Eosinophilic Esophagitis

More on eosinophilic esophagitis: recruiting trials · published research

Related in gastroenterology and liver: MASH (fatty liver disease) · Primary biliary cholangitis · Acid reflux (GERD) · Irritable bowel syndrome · Chronic constipation · Nausea and vomiting

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.